{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:19:15Z","timestamp":1782321555547,"version":"3.54.5"},"reference-count":44,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Plasmablastic lymphoma (PBL) is a rare and aggressive, usually CD20-negative, B-cell lymphoma with features between multiple myeloma and diffuse large B-cell lymphoma. Approximately 120 new cases are diagnosed annually in the United States, and there is a strong association with HIV infection and other immunosuppressive states. It affects mostly adult males, though PBL has been diagnosed in children and immunocompetent individuals. Epstein-Barr virus infection, MYC gene rearrangements, and other mechanisms appear to play a role in PBL lymphomagenesis. Given its rarity, PBL poses distinct diagnostic and therapeutic challenges. A timely diagnosis is essential and requires a high clinical suspicion and a thorough pathological evaluation. The clinical course is aggressive, with a high relapse rate and poor survival with standard therapies. More recently, better outcomes have been observed in patients with early-stage disease treated with combination chemotherapy followed by consolidative radiotherapy. Additionally, advanced disease outcomes may improve with the use of targeted agents, such as proteasome inhibitors and anti-CD38 monoclonal antibodies, when added to combination chemotherapy. Participation in clinical trials and multi-institutional collaboration will be essential to continue improving patient outcomes with PBL.<\/jats:p>","DOI":"10.1182\/hematology.2025000750","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:09:56Z","timestamp":1764943796000},"page":"564-570","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["When immature plasma cells form lymphoma: how to improve on diagnostics and treatment of plasmablastic lymphoma?"],"prefix":"10.1182","volume":"2025","author":[{"given":"Jorge J.","family":"Castillo","sequence":"first","affiliation":[{"name":"Division of Hematological Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"2025120616345456300_hem2025000750C1","first-page":"321","article-title":"Plasmablastic lymphoma","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Stein","year":"2017"},{"issue":"4","key":"2025120616345456300_hem2025000750C2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","article-title":"Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection","volume":"89","author":"Delecluse","year":"1997","journal-title":"Blood"},{"issue":"6","key":"2025120616345456300_hem2025000750C3","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1080\/10428194.2017.1387912","article-title":"Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base","volume":"59","author":"Qunaj","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"2025120616345456300_hem2025000750C4","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","article-title":"The biology and treatment of plasmablastic lymphoma","volume":"125","author":"Castillo","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2025120616345456300_hem2025000750C5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood.2023021348","article-title":"The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma","volume":"143","author":"Di Ciaccio","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2025120616345456300_hem2025000750C6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/bjh.18399","article-title":"Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia","volume":"199","author":"Jessa","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"2025120616345456300_hem2025000750C7","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1038\/s41467-021-25405-w","article-title":"Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma","volume":"12","author":"Frontzek","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"2025120616345456300_hem2025000750C8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2643-3230.BCD-20-0051","article-title":"Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway","volume":"1","author":"Liu","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"10","key":"2025120616345456300_hem2025000750C9","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.3324\/haematol.2020.271957","article-title":"MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma","volume":"106","author":"Ramis-Zaldivar","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"2025120616345456300_hem2025000750C10","doi-asserted-by":"crossref","first-page":"e0318689","DOI":"10.1371\/journal.pone.0318689","article-title":"Genetic subtyping by whole exome sequencing across diffuse large B cell lymphoma and plasmablastic lymphoma","volume":"20","author":"Pomares","year":"2025","journal-title":"PLoS One"},{"key":"2025120616345456300_hem2025000750C11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.humpath.2023.07.009","article-title":"Unraveling the molecular landscape: a comparative analysis of PI3K and MAPK signaling pathways in plasmablastic lymphoma and diffuse large B-cell lymphoma with therapeutic implications","volume":"141","author":"Mansoor","year":"2023","journal-title":"Hum Pathol"},{"key":"2025120616345456300_hem2025000750C12","doi-asserted-by":"crossref","first-page":"1129405","DOI":"10.3389\/fonc.2023.1129405","article-title":"Primary refractory plasmablastic lymphoma: a precision oncology approach","volume":"13","author":"Witte","year":"2023","journal-title":"Front Oncol"},{"key":"2025120616345456300_hem2025000750C13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-2-47","article-title":"Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma","volume":"2","author":"Chang","year":"2009","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2025120616345456300_hem2025000750C14","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/modpathol.3800355","article-title":"Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles","volume":"18","author":"Vega","year":"2005","journal-title":"Mod Pathol"},{"issue":"10","key":"2025120616345456300_hem2025000750C15","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ajh.21250","article-title":"HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases","volume":"83","author":"Castillo","year":"2008","journal-title":"Am J Hematol"},{"issue":"21","key":"2025120616345456300_hem2025000750C16","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1002\/cncr.27551","article-title":"Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy","volume":"118","author":"Castillo","year":"2012","journal-title":"Cancer"},{"issue":"7","key":"2025120616345456300_hem2025000750C17","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3109\/10428194.2015.1113281","article-title":"Plasmablastic lymphoma is treatable in the TT era. A 10 year retrospective by the AIDS Malignancy Consortium","volume":"57","author":"Noy","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2025120616345456300_hem2025000750C18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/annonc\/mdw684","article-title":"Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group","volume":"28","author":"Tchernonog","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"2025120616345456300_hem2025000750C19","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/j.clml.2023.12.014","article-title":"Epidemiologic Characteristics, Treatment Patterns, and Survival Analysis of Plasmablastic Lymphoma in the United States: a SEER and NCDB Analysis","volume":"24","author":"Hansen","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2025120616345456300_hem2025000750C20","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ajh.27376","article-title":"Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Ramirez-Gamero","year":"2024","journal-title":"Am J Hematol"},{"issue":"11","key":"2025120616345456300_hem2025000750C21","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/ajh.25955","article-title":"Survival analysis in treated plasmablastic lymphoma patients: a population-based study","volume":"95","author":"Florindez","year":"2020","journal-title":"Am J Hematol"},{"issue":"19","key":"2025120616345456300_hem2025000750C22","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients","volume":"122","author":"Barta","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2025120616345456300_hem2025000750C23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1634\/theoncologist.2009-0304","article-title":"Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma","volume":"15","author":"Castillo","year":"2010","journal-title":"Oncologist"},{"issue":"11","key":"2025120616345456300_hem2025000750C24","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood.2019003959","article-title":"Impact of MYC in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)","volume":"136","author":"Ramos","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2025120616345456300_hem2025000750C25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjh.15156","article-title":"Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma","volume":"184","author":"Castillo","year":"2019","journal-title":"Br J Haematol"},{"key":"2025120616345456300_hem2025000750C26","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-222063","article-title":"Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma","author":"Arora","year":"2017","journal-title":"BMJ Case Rep"},{"issue":"4","key":"2025120616345456300_hem2025000750C27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00277-016-2601-6","article-title":"Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma","volume":"95","author":"Fedele","year":"2016","journal-title":"Ann Hematol"},{"issue":"2","key":"2025120616345456300_hem2025000750C28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/10428194.2015.1050666","article-title":"Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients","volume":"57","author":"Fernandez-Alvarez","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"2025120616345456300_hem2025000750C29","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1182\/blood-2024-211388","article-title":"Daratumumab with dose-adjusted EPOCH is feasible in newly diagnosed plasmablastic lymphoma: AIDS malignancy consortium 105","volume":"144","author":"Noy","year":"2024","journal-title":"Blood"},{"issue":"16","key":"2025120616345456300_hem2025000750C30","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11164928","article-title":"Targeting CD38 with daratumumab plus chemotherapy for patients with advanced-stage plasmablastoid large B-cell lymphoma","volume":"11","author":"Ryu","year":"2022","journal-title":"J Clin Med"},{"issue":"2","key":"2025120616345456300_hem2025000750C31","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/ajh.26784","article-title":"Outcomes of patients with limited-stage plasmablastic lymphoma: a multi-institutional retrospective study","volume":"98","author":"Hess","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"2025120616345456300_hem2025000750C32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1750-9378-8-28","article-title":"Epstein Barr virus DNA analysis in blood predicts disease progression in a rare case of plasmablastic lymphoma with effusion","volume":"8","author":"Friis","year":"2013","journal-title":"Infect Agent Cancer"},{"issue":"2","key":"2025120616345456300_hem2025000750C33","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1111\/bjh.18228","article-title":"Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma","volume":"198","author":"Dittus","year":"2022","journal-title":"Br J Haematol"},{"issue":"12","key":"2025120616345456300_hem2025000750C34","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.bbmt.2014.06.009","article-title":"Hematopoietic cell transplantation for plasmablastic lymphoma: a review","volume":"20","author":"Al-Malki","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2025120616345456300_hem2025000750C35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000504608","article-title":"bortezomib- and lenalidomide- based treatment of refractory plasmablastic lymphoma","volume":"43","author":"Ando","year":"2020","journal-title":"Oncol Res Treat"},{"issue":"10","key":"2025120616345456300_hem2025000750C36","doi-asserted-by":"crossref","first-page":"E390","DOI":"10.1002\/ajh.26291","article-title":"Complete response to pembrolizumab and radiation in a patient with HIV-negative, EBV-positive plasmablastic lymphoma","volume":"96","author":"Castillo","year":"2021","journal-title":"Am J Hematol"},{"issue":"12","key":"2025120616345456300_hem2025000750C37","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1200\/JCO.2012.46.9593","article-title":"Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia","volume":"31","author":"Holderness","year":"2013","journal-title":"J Clin Oncol"},{"key":"2025120616345456300_hem2025000750C38","first-page":"8331766","article-title":"Martin BA, Abdulhaq H","volume":"2022","author":"Lee","year":"2022","journal-title":"Case Rep Hematol"},{"issue":"5","key":"2025120616345456300_hem2025000750C39","first-page":"287","article-title":"Bortezomib in plasmablastic lymphoma: a case report and review of the literature","volume":"36","author":"Saba","year":"2013","journal-title":"Onkologie"},{"issue":"1-2","key":"2025120616345456300_hem2025000750C40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000455146","article-title":"A case of plasmablastic lymphoma achieving complete response and durable remission after lenalidomide- based therapy","volume":"40","author":"Schmit","year":"2017","journal-title":"Oncol Res Treat"},{"issue":"1","key":"2025120616345456300_hem2025000750C41","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/ejh.12286","article-title":"CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab","volume":"93","author":"Yan","year":"2014","journal-title":"Eur J Haematol"},{"key":"2025120616345456300_hem2025000750C42","doi-asserted-by":"crossref","first-page":"104551","DOI":"10.1016\/j.critrevonc.2024.104551","article-title":"BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: case report and literature review","volume":"205","author":"Feng","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"2025120616345456300_hem2025000750C43","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjh.19571","article-title":"B-cell maturation antigen-directed bispecific antibodies in plasmablastic lymphoma","volume":"205","author":"Hofer","year":"2024","journal-title":"Br J Haematol"},{"issue":"5","key":"2025120616345456300_hem2025000750C44","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006684","article-title":"BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma","volume":"11","author":"Raghunandan","year":"2023","journal-title":"J Immunother Cancer"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/564\/2470103\/564castillo.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2025\/1\/564\/2470103\/564castillo.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T21:35:00Z","timestamp":1765056900000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2025\/1\/564\/556845\/When-immature-plasma-cells-form-lymphoma-how-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2025,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2025000750","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,5]]},"published":{"date-parts":[[2025,12,5]]}}}